Clinical Trial Update: Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer- [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating neoadjuvant chemoradiotherapy plus sintilimab for microsatellite-stable locally advanced rectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Tyvyt (Sintilimab) (Sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Rectal Cancer | Phase 2 | Status: WITHDRAWN